Aug 14 (Reuters) - Prima BioMed Ltd PRR.AX :
* Announces commencement of milestones for imp701 program
* Will receive undisclosed clinical milestone payment from collaboration,
licensing agreement with Novartis
* Says collaboration and licensing agreement with Novartis relating to its
phase i imp701 lag-3 antibody
* Prima is eligible to receive further potential development-based milestone
payments and royalties on sales following commercialisation
* Says phase i imp701 lag-3 antibody is being trialled for the treatment of
cancer
* Source text for Eikon ID:nMKWcFmmRa
* Further company coverage PRR.AX